Mineralys Therapeutics, Inc. (MLYS) Tops Q3 EPS by 19c

Mineralys Therapeutics, Inc. (NASDAQ: MLYS) reported Q3 EPS of ($0.57), $0.19 better than the analyst estimate of ($0.76).

For earnings history and earnings-related data on Mineralys Therapeutics, Inc. (MLYS) click here.

You May Also Be Interested In

• Micron offers Taiwan workers up to 68-month bonuses as strike threat looms
• Brinker Int'l (EAT) PT Lowered to $240 at DA Davidson Ahead of Analyst Day
• Kroger (KR) Tops Q2 EPS by 3c, Misses on Revenue; Offers FY27 EPS Guidance